Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 204.86% is 12% below its 5-year average of 231.59%, around the middle of its 5-year range (129.28%–344.21%).
As of the fiscal period ended Tuesday, June 30, 2026. 13.00% below its 12-month average of 235.48%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 204.86%.
DEBT TO ASSETS RATIO
204.86%
DEBT TO ASSETS RATIO AVG TTM
235.48%
DEBT TO ASSETS RATIO AVG 3Y
245.02%
DEBT TO ASSETS RATIO AVG 5Y
231.59%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-13.00%
CURRENT VS 3Y AVG
-16.39%
CURRENT VS 5Y AVG
-11.54%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13%
median of 374 covered companies
CURRENT VS SECTOR MEDIAN
+157485.71%
vs the sector median at left
BridgeBio Pharma, Inc.
Market Cap
$12.95B
Debt to Assets Ratio
204.86%
TTM Avg
235.48%
3Y Avg
245.02%
5Y Avg
231.59%
Market Cap
$12.89B
Debt to Assets Ratio
0.21%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.19B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.52B
Debt to Assets Ratio
0.49%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.17B
Debt to Assets Ratio
0.40%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.00B
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.16B
Debt to Assets Ratio
0.20%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | $12.95B | 204.86% | 235.48% | 245.02% | 231.59% |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 0.21% | N/A | N/A | N/A |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 0.01% | N/A | N/A | N/A |
| Baxter International Inc. (BAX)vs › | $12.52B | 0.49% | N/A | N/A | N/A |
| Penumbra, Inc. (PEN)vs › | $12.49B | 0.11% | N/A | N/A | N/A |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.17B | 0.40% | N/A | N/A | N/A |
| Encompass Health Corporation (EHC)vs › | $12.00B | 0.38% | N/A | N/A | N/A |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | 0.20% | N/A | N/A | N/A |
| DaVita Inc. (DVA)vs › | $11.47B | 0.61% | N/A | N/A | N/A |
| Bio-Techne Corporation (TECH)vs › | $11.36B | 0.11% | N/A | N/A | N/A |
Debt/Assets
204.9%
Debt/Equity
N/A
Current Ratio
1.23
Interest Coverage
-10.7x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 204.86% |
| 2026-03-31 | 246.90% |
| 2025-12-31 | 291.52% |
| 2025-09-30 | 186.30% |
| 2025-06-30 | 247.84% |
| 2025-03-31 | 210.77% |
| 2024-12-31 | 188.24% |
| 2024-09-30 | 260.12% |
| 2024-06-30 | 217.69% |
| 2024-03-31 | 203.54% |
| 2023-12-31 | 318.43% |
| 2023-09-30 | 264.89% |
| 2023-06-30 | 344.21% |
| 2023-03-31 | 276.32% |
| 2022-12-31 | 276.64% |
| 2022-09-30 | 235.44% |
| 2022-06-30 | 198.53% |
| 2022-03-31 | 212.50% |
| 2021-12-31 | 170.44% |
| 2021-09-30 | 179.01% |
| 2021-06-30 | 129.28% |
| 2021-03-31 | 126.45% |
| 2020-12-31 | 70.47% |
| 2020-09-30 | 61.41% |
| 2020-06-30 | 52.95% |
| 2020-03-31 | 47.74% |
| 2019-12-31 | 14.53% |
| 2019-09-30 | 11.71% |
| 2019-06-30 | 23.04% |
| 2019-03-31 | 13.67% |
| 2018-12-31 | 11.72% |
